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ABSTRACT 1 
Dysbiotic gut microbiota have been implicated in human disease. Diet-based therapeutic 2 
strategies have been utilised to manipulate the gut microbiota towards a more favourable 3 
profile. However, it has been demonstrated that large inter-individual variability exists in gut 4 
microbiota response to a dietary intervention. The primary objective of this study was to 5 
investigate whether habitually low (LDF) versus high dietary fibre (HDF) intakes influence 6 
gut microbiota response to an inulin-type fructan prebiotic. In this randomised, double-blind, 7 
placebo-controlled, cross-over study, 34 healthy participants were classified as LDF or HDF 8 
consumers. Gut microbiota composition (16S rRNA bacterial gene sequencing) and short-9 
chain fatty acid concentrations  were assessed following 3 weeks of daily prebiotic 10 
supplementation (Beneo Orafti® Synergy 1; 16 g/d) or placebo (Roquette Glucidex® 29 11 
Premium; 16 g/d) as well as after 3 weeks of the alternative intervention, following a 3-week 12 
washout period. In the LDF group, the prebiotic intervention led to an increase in 13 
Bifidobacterium (p = 0.001). In the HDF group, the prebiotic intervention led to an increase 14 
in Bifidobacterium (p < 0.001) and Faecalibacterium (p = 0.010) and decreases in 15 
Coprococcus (p = 0.010), Dorea (p = 0.043) and Ruminococcus (Lachnospiraceae family) (p 16 
= 0.032). This study demonstrates that those with HDF intakes have a greater gut microbiota 17 
response and are therefore more likely to benefit from an inulin-type fructan prebiotic than 18 
those with LDF intakes. Future studies aiming to modulate the gut microbiota and improve 19 
host health, using an inulin-type fructan prebiotic, should take habitual dietary fibre intake 20 
into account. 21 
 22 
INTRODUCTION 23 
The commensal microbes that reside within the gastrointestinal tract are implicated in human 24 
health and disease. Host genetics (1), life stage, geographical location (2), gender (3) and 25 
antibiotic use (4) influence gut microbiota composition; however, diet plays a major role in 26 
modulating the community of microbes that reside within the gut (5). Dietary interventions 27 
provide an opportunity to manipulate the commensal bacteria towards a more favourable 28 
profile to help enhance human health.      29 
 Numerous studies have demonstrated that dietary interventions can elicit significant 30 
changes in gut microbiota composition and short-chain fatty acid (SCFA) production. In a 31 
recent study, a short-term plant-based diet high in grains, legumes, fruits and vegetables or an 32 
animal-based diet composed of meat, eggs and cheese led to distinct shifts in bacterial 33 
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relative abundance. Interestingly, the animal-based diet had a larger effect on the gut 34 
microbiota than the plant-based diet (6). Another study demonstrated that a three-week 35 
intervention containing high levels of wholegrains or red meat altered numerous bacterial 36 
taxa, including Collinsella aerofaciens and certain Clostridium spp., and led to an increase in 37 
microbial diversity during the high wholegrain dietary phase (7). Dietary intake in 38 
economically-developed countries is characterised by intakes of dietary fibre well below 39 
recommendations, thus depriving the gut microbiota of valuable fermentable substrates (8,9). 40 
One method of enriching the diet to positively modulate the gut microbiota is to supplement 41 
it with prebiotics. Prebiotics are “a substrate that is selectively utilized by host 42 
microorganisms conferring a health benefit” (10).  43 
It is becoming increasingly evident that there is profound inter-individual variability 44 
in gut microbiota response to dietary interventions. Preliminary research has suggested that 45 
factors such as microbial diversity, baseline bifidobacteria concentrations and habitual diet 46 
are implicated in gut microbiota responsiveness. A study undertaken by Tap and co-authors 47 
(11) demonstrated that a short-term alteration in dietary fibre intake in 19 healthy adults led 48 
to differing microbial responses among participants. Participants with higher baseline 49 
microbial richness had gut microbiota that were more resilient to change and, therefore, less 50 
responsive to the change in dietary fibre intake. Several studies have also established a link 51 
between baseline bifidobacteria concentrations and change in bifidobacteria in response to a 52 
dietary intervention (12–16). Increases in bifidobacteria concentrations are more pronounced 53 
in individuals with lower baseline bifidobacteria compared to individuals with higher 54 
baseline bifidobacteria concentrations. Preliminary research has shown that habitual diet may 55 
also influence gut microbiota responsiveness (17,18). AA 21-day palm date intervention did 56 
not influence the numbers of select bacterial taxa, however, secondary analysis demonstrated 57 
that those with HDF intakes hosted microbiota that were more stable in response to the palm 58 
date intervention than those with LDF intakes (17).  59 
To date, no human studies have been conducted with the primary aim of determining 60 
whether habitual dietary intake influences gut microbiota responsiveness to a dietary 61 
intervention. Therefore, we aimed to investigate the influence of differing habitual dietary 62 
fibre intakes on the responsiveness of the gut microbiota to an inulin-type fructan prebiotic. 63 
 64 
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METHODS 65 
This randomised, double-blind, placebo-controlled, cross-over, human intervention study was 66 
conducted at Massey University, Palmerston North, New Zealand between March and August 67 
2016. The Massey University Human Ethics Committee approved the study (Massey 68 
University HEC: Southern A application- 15/34). The study is registered in the Australian 69 
New Zealand Clinical trials registry (ACTRN12615000922572). The study protocol has 70 
previously been published (19). 71 
 72 
Participants 73 
Participants were recruited through email and poster advertisement around Palmerston North, 74 
New Zealand. A total of forty-four eligible participants provided written informed consent to 75 
participate in this human intervention study (Figure 1). Participants completed a screening 76 
questionnaire to ensure they met the following inclusion criteria: aged between 19 and 65 77 
years; BMI between 18.5 and 30 kg/m2; healthy (self-reported and confirmed by a health 78 
screening blood test [liver and kidney function, blood glucose levels, electrolytes, complete 79 
blood count, calcium and C reactive protein] using standard clinical cut-offs). Exclusion 80 
criteria included: a significant change in weight (± 5% of total body weight) or dietary intake 81 
over the past year; taken antibiotics within the past 6 months; consumption of supplementary 82 
prebiotics or probiotic containing foods, drinks and supplements within the past 1 month; 83 
pregnancy or breastfeeding (or plans for a pregnancy within the following 3 months); food 84 
intolerances associated with gastrointestinal upset; current smoker and high alcohol consumer 85 
(> 15 standards drinks per week for males or > 10 standard drinks per week for females, and 86 
less than 2 days per week alcohol free).  87 
Participants were also selected based on their habitual dietary fibre intakes. All 88 
eligible participants completed a validated habitual dietary fibre intake food frequency 89 
questionnaire (DF-FFQ) (20) during the screening phase of the study to determine whether 90 
they were low, moderate or high dietary fibre consumers. Only participants categorised with 91 
low (< 18 g/d for females and < 22 g/d for males) or high (≥ 25 g/d for females and ≥ 30 g/d 92 
for males) dietary fibre intakes were invited to participate in the study. The HDF categories 93 
were chosen to reflect the New Zealand recommended dietary fibre intake which is > 25 g/d 94 
for females and > 30 g/d for males (21). The LDF categories were chosen as the average 95 
dietary fibre intake in New Zealand is 17.5 g/d for females and 22.1 g/d for males which is 96 
well below the recommended dietary fibre intakes (22). To ensure that categorisation into low 97 
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and high dietary fibre groups was as accurate as possible, once recruited, participants 98 
completed four 3-day diet records. If the average dietary fibre intake from these records was 99 
outside of the pre-defined categories described above, the participants’ data were excluded 100 
from the analysis.  101 
 102 
Interventions 103 
The two interventions were either 16 g/d of powdered inulin-type fructan prebiotic (Beneo 104 
Orafti® Synergy1- 50:50 inulin to fructo-oligosaccharide mix) as two 8 g/d doses for three 105 
weeks or 16 g/d of powdered placebo (Roquette Glucidex® 29 Premium- digestible 106 
maltodextrin) as two 8 g/d doses for three weeks. The two doses were consumed 30 min 107 
before breakfast and 30 min before dinner mixed into hot or cold beverages that the 108 
participants regularly consumed. A washout period of three weeks was undertaken between 109 
the two intervention phases (Figure 1). Both interventions were presented in identical 110 
packaging and the powders were similar in taste and appearance and were both low in 111 
calories (prebiotic 34 kcal/d; placebo 62 kcal/d). Participants were advised not to change their 112 
habitual dietary intake or physical activity levels, or take supplementary prebiotics or 113 
probiotic containing foods, drinks or supplements for the duration of the study. 114 
 115 
Study design 116 
Participants attended an initial screening visit to the research unit where a fasted health 117 
screening blood sample was taken. Body composition was assessed using air displacement 118 
plethysmography (BodPod®; participants were fasted and wore skin tight clothing) and 119 
weight and height measurements were taken (Figure 2). Eligible participants were then 120 
randomised to one of two intervention orders (i.e. prebiotic then placebo or placebo then 121 
prebiotic) (Figure 1). The intervention order was randomised using a computer-based pre-122 
generated intervention order. The researcher involved in participant recruitment and data 123 
collection, and the participants were blinded to the intervention order. Participants completed 124 
a participant questionnaire at the beginning of the study. They also completed a 3-day diet 125 
record & appetite questionnaire, fructan food frequency questionnaire (Fructan-FFQ), and 126 
had a weight measurement taken at the beginning and end of each intervention phase. A daily 127 
diary was completed by each participant during both intervention phases to assess compliance 128 
to the intervention, stool frequency and gastrointestinal symptoms. A fresh faecal sample was 129 
voided at the beginning and end of each intervention phase into a sterile container, 130 
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immediately sealed in an anaerobic bag containing an anaerobic sachet and stored at -20oC 131 
until processing (Figure 2). 132 
 133 
Dietary intake analysis 134 
Nutrient intake and food group serves were evaluated using four 3-day diet records. The 3-135 
day diet records were completed on the three days leading up to the start of each intervention 136 
phase and the last three days of each intervention phase. The information collected in the 3-137 
day diet records was entered into FoodWorks version 8.0 (Xyris Software Pty Ltd) by a 138 
registered Dietitian. The Australian database in FoodWorks was used (AusBrands and 139 
AusFoods 2015 data sources) so nutrient intake and food group analysis could be conducted. 140 
Due to the absence of data regarding inulin-type fructan composition in dietary 141 
analysis software, fructan intake from diet was evaluated using a validated Fructan-FFQ (23). 142 
Four Fructan-FFQs were completed during the study, one at the beginning and one at the end 143 
of each intervention phase. The Fructan-FFQ comprised twenty-three food and drink items 144 
contributing to inulin and oligofructose intake. For each food or drink item, participants 145 
indicated the usual portion size (i.e. small, medium or large) and the number of portions 146 
consumed in the previous 7 days. Inulin and oligofructose consumed from food commodities 147 
(i.e. onion or garlic), were determined using published food composition data (24), whereas 148 
for composite foods (i.e. noodles and biscuits) the inulin and oligofructose intakes were 149 
determined first by calculating the food commodity content (i.e. wheat) of the composite food 150 
using the Food Commodity Intake Database (US Department of Agriculture and the US 151 
Environmental Protection Agency, USA) and then calculating the inulin and oligofructose 152 
amounts of each food commodity present in each composite food item, as previously 153 
performed (25). Portion sizes were estimated using standard portion size information (26).    154 
 155 
Appetite rating analysis 156 
Appetite rating was evaluated using an anchored 100 mm visual analogue scale (27). Hunger, 157 
fullness, satisfaction and how much can be consumed were assessed. Participants were 158 
instructed to mark with a cross at the point on the scale where they felt the cross best 159 
represented their appetite at the time the questionnaire was completed. Appetite ratings were 160 
assessed 30 min before and 30 min after main meals (breakfast, lunch and dinner) on the 161 
three days leading up to the start of each intervention phase and the last three days of each 162 
intervention phase. 163 
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 164 
Bacterial DNA extraction 165 
Faecal microbiota were measured using 16S rRNA bacterial gene sequencing and 166 
bifidobacteria concentrations were analysed using quantitative polymerase chain reaction 167 
(PCR). Bacterial DNA was extracted from the faecal samples using the MoBio PowerLyzer® 168 
Powersoil DNA® isolation kit according to the manufacturer’s instructions with minor 169 
alterations. Faecal subsamples were taken from the outer region of the sample only (to reduce 170 
variability) and weighed (0.25 ± 0.025 g) into PowerLyzer® glass bead tubes. A FastPrep-171 
24™ 5G (MP Biomedicals) was used to homogenise the samples at a speed of 5.5 m/sec for 172 
four 90 sec cycles with a 60 sec break between each cycle. The DNA was eluted in 10 mM 173 
Tris. NanoDrop 1000 spectrophotometry was used to quantify the DNA concentration.  174 
 175 
16S rRNA bacterial gene sequencing 176 
The extracted bacterial DNA was used as a template for initial PCR amplification of the V3-177 
V4 hyper-variable region of the 16S rRNA bacterial gene using the barcoded fusion primers: 178 
16SR_V4 (5′-CAAGCAGAAGACGGCATACGAGAT-barcode-AGTCAGTCAGCCGGAC 179 
TACHVGGGTWTCTAAT-3′) and 16SF_V3 (5′-AATGATACGGCGACCACCGAGATCT 180 
ACAC-barcode-TATGGTAATTGGCCTACGGGAGGCAGCAG-3′), which also contain 181 
adaptors for downstream Illumina MiSeq sequencing. Each sample was amplified with a pair 182 
of unique (8 base) barcoded primers. The PCR reagents used were Invitrogen AccuPrime™ 183 
Pfx SuperMix (part number 12344-040) (17 µL), 10 μM 16SR_V4 Primer (1 μL), 10 μM 184 
16SF_V3 Primer (1 μL) and Ambion nuclease-free water (catalog number: AM9932) to 185 
normalise to 5 ng/µL (1 µL). The following PCR conditions were used; a hold at 95 °C for 2 186 
min followed by 30 cycles of 95°C for 20 sec (denaturation), 55°C for 15 sec (annealing), 187 
72°C for 5 min (extension) finishing with a hold at 72°C for 10 min. Library clean-up utilised 188 
an Invitrogen SequalPrep Normalisation Plate Kit (Thermo Fisher). Eighteen µL of the PCR 189 
product was used in the library clean-up with an elution volume of 12 µL. A Qubit DNA high 190 
sensitivity assay was used to measure the library concentration and a Bioanalyzer DNA HS 191 
assay was used for library sizing. The libraries were pooled by equal volume. Sequencing 192 
was undertaken on an Illumina MiSeq machine, using 2 x 250 base pair (bp) read length, at 193 
the Massey Genome Service (Massey University, Palmerston North, New Zealand). 194 
The data obtained from Illumina MiSeq sequencing were analysed using Quantitative 195 
Insights Into Microbial Ecology (QIIME) (28). Paired-end assembler for DNA sequencing 196 
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(PANDAseq) was used to assemble the forward and reverse reads into continuous sequences 197 
ensuring at least a 50 bp overlap with a minimum of 350 bp and a maximum of 500 bp length 198 
(29). Chimera filtered sequences and reads were clustered into operational taxonomic units 199 
based on an identity threshold value of 97% using USEARCH 6.1 and UCLUST (30). 200 
Sequence alignment with the Greengenes core reference database (version 13_5) was carried 201 
out using PyNAST (31). The RDP Naïve Bayesian classifier was used to provide taxonomic 202 
assignment (32). As there was variation in the library size (33,906 to 196,843 reads) and the 203 
potential for differing sequencing depths, which could bias the diversity metric calculations, 204 
all samples were rarefied to 33,000 reads. Sequencing data is available from the NCBI 205 
Sequence Read Achieve under study SRP120250; BioProject PRJNA414683 206 
(https://www.ncbi.nlm.nih.gov/Traces/study/?acc=SRP120250).  207 
 208 
Quantitative PCR 209 
In addition to 16S rRNA bacterial gene sequencing, quantitative PCR analysis of 210 
bifidobacteria was undertaken as it provides direct quantification and previous research, 211 
utilising this technique, has demonstrated that bifidobacteria response to certain dietary 212 
interventions is influenced by baseline concentrations (12–16). Therefore, bifidobacteria 213 
concentrations were determined using the LightCycler® 480 system (Roche Life Science). 214 
Standard template DNA was prepared using Bifidobacterium bifidium (DSM20082). 215 
Bifidobacterium bifidum was grown in MRS (De Man, Rogosa, Sharpe) broth (Oxoid, 216 
Adelaide, Australia) + 0.05% cysteine at 37°C for 2 days under anaerobic conditions. The 217 
culture was counted using a haemocytometer and adjusted to a final concentration of 1 × 109 218 
cells/mL. Bacterial DNA was extracted using the MoBio PowerLyzer® Powersoil DNA® 219 
isolation kit as described above. The following primers were used: forward 220 
(GGGTGGTAATGCCGGATG) and reverse (CCACCGTTACACCGGGAA) primers (33). 221 
Quantitative PCR was performed in triplicate with 10 µL of SyBr Green Master (Roche Life 222 
Science), 1 µL of each of the forward and reverse primers (5 µM), 7 µL of PCR grade water 223 
and 1 µL of template DNA. The conditions used for PCR amplification were initial 224 
denaturation at 95°C for 5 min followed by 40 cycles of denaturation (95°C for 1 min), 225 
annealing (66°C for 45 sec), extension (72°C for 1 min) and finished with a melt curve (95°C 226 
for 30 sec, 65°C for 1 min and 95°C continuous– 5 per °C acquisitions). 227 
 228 
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Faecal short-chain fatty acid analysis 229 
Short-chain fatty acids were measured by gas chromatography (GC) using a modified known 230 
method (34). While still frozen, 0.5 g to 1.0 g of faecal sample was weighed into a 15 mL 231 
Eppendorf tube; 0.01 M phosphate buffered saline containing 2-ethylbutyric acid (5.56 mM) 232 
as an internal standard was added to the faecal sample to make an aqueous faecal solution 233 
(dilution factor of 10) containing 5 mM 2-ethylbutyric acid. The samples were kept on ice 234 
and mixed to disperse faecal matter. Aqueous faecal solutions were centrifuged at 3000 x g 235 
for 10 min (4°C), 500 µL of the supernatant was transferred to a 2 mL Eppendorf tube and 236 
was acidified with 250 µL concentrated hydrochloric acid and 1000 µL diethyl ether added. 237 
Following a 10 sec vortex, to allow acids to transfer to the diethyl ether phase, the samples 238 
were centrifuged at 10,000 x g for 5 min (4°C). In a capped GC vial 100 µL of the diethyl 239 
ether phase was derivatised with 20 µL N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide 240 
with 1% tert-butyldimethylchlorosilane (MTBSTFA + TBDMSCI, 99:1; Sigma-Aldrich) in a 241 
water bath at 80°C for 20 min. Once cooled, the derivatised sample was transferred to a 200 242 
µL vial insert and recapped. To ensure complete derivatisation, the samples were left for 48 h 243 
at room temperature before analysis using GC. Standards containing 2-ethylbutyric acid (5 244 
mM) as an internal standard were prepared for derivatisation alongside the samples.  245 
Analysis was performed on a Shimadzu capillary gas chromatograph system (GC-246 
2010 Plus, Tokyo, Japan) equipped with a flame ionisation detector and fitted with a Restek 247 
column (SH-Rtx-1, 30 m × 0.25 mm ID × 0.25 µm) (Shimadzu, USA). The carrier gas was 248 
helium with a total flow rate of 21.2 mL/min and pressure of 131.2 kPa. Make-up gas was 249 
nitrogen. The temperature program began at 70°C increasing to 115°C at 6°C/min, with a 250 
final increase to 300°C at 60°C/min, holding for 3 min. Flow control mode was set to linear 251 
velocity; 37.5 cm/sec. Injector temperature was 260°C and detector temperature was 310°C. 252 
Samples were injected (1 µL) with a split injection (split ratio 10:1). The GC instrument was 253 
controlled and data processed using Shimadzu GC Work Station LabSolutions Version 5.3. 254 
Data acquired provided a final sample result of µmol SCFA/g wet faeces. 255 
 256 
Sample size calculations 257 
In order to detect a significant difference in responsiveness of the key phylum and genera (i.e. 258 
Actinobacteria, Lactobacillus, Faecalibacterium, Bifidobacterium) to the prebiotic 259 
intervention (difference of 3% in bacterial composition with a variance of 9% between and 260 
within individuals) between the LDF and HDF groups (with a power of 80% and significance 261 
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of 5%) thirty-four participants were required (35). To allow for participant withdrawal we 262 
aimed to recruit approximately forty participants. 263 
 264 
Statistical analysis 265 
Mann-Whitney tests were used to determine whether there were significant differences in 266 
baseline (start of intervention phase 1) bacterial taxa, SCFA concentrations and dietary 267 
intakes (fructan intakes, nutrient intakes and food group serves) between the LDF and HDF 268 
groups. One-way repeated measures analysis of variance (ANOVA) was used to determine 269 
whether nutrient intakes changed throughout the duration of the study in the whole cohort. 270 
Differences in participant characteristics between the LDF and HDF groups were assessed 271 
using t-tests and Chi-squared tests. McNemar’s tests were used to determine whether there 272 
were any differences in gastrointestinal symptom frequency during the placebo and prebiotic 273 
intervention phases in the whole cohort and the LDF and HDF groups. Differences in 274 
bacterial taxa and SCFA concentrations between the start of intervention phase 1 (baseline) 275 
and start of intervention phase 2 (after the washout period) where determine using a Mann-276 
Whitney test. Mann-Whitney test was also used to determine whether the bacterial taxa or 277 
SCFA concentrations changed during the placebo intervention phase. Two-way repeated 278 
measures ANOVA, blocked by participant, were used to determine whether there were 279 
differences in appetite ratings, SCFA concentrations and bacterial taxa during the prebiotic 280 
and placebo intervention phases in the whole cohort and the LDF and HDF groups. Two-way 281 
repeated measures ANOVA, blocked by participant, was also used to determine whether 282 
there were differences in prebiotic driven gut microbiota response between the LDF and HDF 283 
groups. Bacterial taxa with skewed data were log transformed to help normalise the data. 284 
Only genus level bacteria with a mean relative abundance of >1% were included in the 285 
analysis unless a genus (i.e. Faecalibacterium and Lactobacillus) has been shown in the 286 
literature to be influenced by inulin-type fructan prebiotics (36). PERMANOVA analysis 287 
(adonis procedure in R package vegan) was undertaken, using the relative abundances for the 288 
unweighted UniFrac distance, to determine whether the gut microbiota community changes 289 
that occurred differed significantly between the LDF and HDF groups. Spearman’s rank 290 
correlation test was used to analyse the correlation between baseline (start of intervention 291 
phase 1) bifidobacteria concentrations and change in bifidobacteria concentrations after the 292 
prebiotic intervention. Statistical analysis was carried out using Genstat version 17.1.0.14713 293 
or R package vegan version 2.4-4. QIIME (28) was used to conducted the statistical analysis 294 
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(non-parametric two-sample t-test) to compare baseline (start of intervention phase 1) alpha 295 
diversity between the dietary fibre groups and the change in alpha diversity in the LDF and 296 
HDF groups after the prebiotic intervention. 297 
 298 
RESULTS 299 
Participants 300 
Of the forty-four eligible participants who provided informed consent to participate in the 301 
study, four did not complete the study as they either experienced severe gastrointestinal 302 
symptoms (i.e. disabling abdominal pain, cramps and bloating) due to the prebiotic (n = 2) or 303 
were prescribed antibiotics at the beginning of the study (n = 1). One participant was also 304 
prescribed antibiotics at the end of the study (during the placebo intervention phase), 305 
however, the data collected during the prebiotic intervention phase were still able to be used. 306 
Forty participants completed the study, however, the data from seven participants were 307 
excluded as the participants were either assessed as being moderate dietary fibre consumers, 308 
based on the data collected from the four 3-day diet records (n = 6), or were found to have 309 
consumed supplementary prebiotics and probiotic containing foods and drinks during the 310 
study (n = 1). The data collected from thirty-four participants were used for the prebiotic 311 
intervention analysis and the data collected from thirty-three participants were used for the 312 
placebo intervention analysis (Figure 1).  313 
 314 
Baseline dietary intake and participant characteristic differences 315 
Categorisation into different dietary fibre intake groups was successful as dietary fibre 316 
intakes were significantly different (p < 0.001) between the LDF (n = 14; 18.0 g/d) and HDF 317 
(n = 20; 38.6 g/d) groups. There were several additional significant differences (p < 0.05) in 318 
baseline nutrient intakes between the LDF and HDF groups. HDF consumers had higher 319 
energy, total fat, polyunsaturated fat, monounsaturated fat, carbohydrate and dietary fibre per 320 
1000 kJ compared to the LDF group. There were, however, no differences in fructan intake 321 
between the two groups (Table 1). Energy from fat (%) and energy from protein (%) were 322 
not significantly different, however, energy from fibre (%) was significantly different 323 
between dietary fibre groups (p < 0.001). Therefore, the only macronutrient that continued to 324 
be significantly different between dietary fibre groups after energy intakes were controlled 325 
for was dietary fibre (Table 1). The LDF group had a lower intake of fruits (p = 0.009), 326 
vegetables (p < 0.001) (dark green [p = 0.007] and red orange vegetables [p = 0.039]), protein 327 
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foods (p = 0.036) and nuts and seeds (p = 0.001) compared to the HDF group (Figure 3). 328 
Dietary intakes did not change throughout the duration of the study (Supplemental Table 1). 329 
Despite similar age, sex and BMI, there were significant differences in body composition 330 
between the two dietary fibre groups. The LDF group had a significantly lower fat free mass 331 
(p = 0.021) and significantly higher fat mass (p = 0.021) compared to the HDF group (Table 332 
2).  333 
 334 
Baseline SCFA concentration and microbiota differences  335 
Of the 138 faecal samples analysed, a total of 12,420,607 high quality 16S rRNA bacterial 336 
gene sequence reads were generated. The average number of sequence reads generated per 337 
faecal sample was 90,004 (33,906 to 196,843 reads per sample).  338 
There were no significant baseline differences in SCFA concentrations (Table 3) or 339 
any of the alpha diversity indices measured (Observed species, Shannon, Chao and 340 
PD_whole tree) (Supplemental Table 2) between the LDF and HDF groups. At baseline the 341 
relative abundance of an unknown genus of Lachnospiraceae (other) was significantly higher 342 
in the LDF group compared to the HDF group ( p = 0.043). The LDF group also had a trend 343 
towards a higher relative abundance of Bifidobacterium compared to the HDF group; 344 
however, statistical significance was not reached (p = 0.066) (Table 3).  345 
 346 
Gastrointestinal symptoms  347 
In the whole cohort, the frequency of mild and severe gastrointestinal symptoms were 348 
statistically similar (p > 0.05) during the placebo and prebiotic intervention phases. There 349 
was, however, a significantly higher frequency of moderate symptoms (p = 0.013), 350 
particularly moderate flatulence (p = 0.012), experienced during the prebiotic compared to 351 
the placebo intervention phase (Supplemental Table 3).  352 
After categorisation into dietary fibre intake groups, the HDF group also experienced 353 
an increased frequency of moderate symptoms (p = 0.004), particularly moderate flatulence 354 
(p = 0.016), during the prebiotic compared to the placebo intervention phase. There were no 355 
significant differences in gastrointestinal symptom frequency between the placebo and 356 
prebiotic intervention phases in the LDF group (Supplemental Table 3).  357 
 358 
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Prebiotic driven changes in appetite ratings 359 
In the whole cohort, there were no significant differences in appetite ratings before or after 360 
breakfast, lunch or dinner during the prebiotic intervention phase (Supplemental Table 4).  361 
After categorising participants based on their dietary fibre intakes, appetite ratings did 362 
not significantly change before or after breakfast, lunch or dinner during the prebiotic 363 
intervention phase in the LDF group (Supplemental Table 5). There were, however, a 364 
number of significant changes in appetite ratings during the prebiotic intervention phase in 365 
the HDF group. The prebiotic intervention led to a significant reduction in satisfaction before 366 
lunch (p = 0.042) and in hunger after dinner (p = 0.006), and a significant increase in fullness 367 
(p = 0.002) and satisfaction after lunch (p = 0.044) (Supplemental Table 6). 368 
 369 
Prebiotic driven changes in SCFA concentrations and microbiota  370 
Gut microbiota composition and SCFA concentrations after the washout period were not 371 
significantly different from baseline (data not presented). There were also no significant 372 
changes in gut microbiota composition or SCFA concentrations during the placebo 373 
intervention phase (data not presented). 374 
In the whole cohort, there were no significant changes in SCFA concentrations due to 375 
the prebiotic intervention (Table 4). There were, however, a number of prebiotic driven 376 
changes in bacterial taxa. At a phylum level, Actinobacteria relative abundance significantly 377 
increased (p < 0.001) and Firmicutes relative abundance significantly decreased (p = 0.007). 378 
There was also a trend towards a reduction in Proteobacteria relative abundance (p = 0.070) 379 
during the prebiotic intervention phase (Table 4). At a genus level, there was a prebiotic 380 
driven increase in the relative abundance of Bifidobacterium (p < 0.001) and a reduction in 381 
Coprococcus (p = 0.016), Dorea (p = 0.029), Ruminococcus (Lachnospiraceae family) (p = 382 
0.007) and Oscillospira relative abundance (p = 0.031). There was also a trend towards an 383 
increase in Faecalibacterium relative abundance (p = 0.088) during the prebiotic intervention 384 
phase (Table 4).   385 
After categorisation into dietary fibre intake groups, there were no significant 386 
prebiotic driven changes in SCFA concentrations in the LDF (Supplemental Table 7) or 387 
HDF groups (Supplemental Table 8) which was consistent with the whole cohort analysis 388 
(Table 1). At a phylum level, both dietary fibre groups had a significant increase in 389 
Actinobacteria relative abundance (LDF p = 0.007 and HDF p = <0.001); however, the 390 
reduction in Firmicutes relative abundance was only significant in the HDF group (LDF p = 391 
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0.127 and HDF p = 0.027) (Figure 4 + Supplemental Tables 7 & 8). At a genus level, the 392 
only significant change that occurred during the prebiotic intervention in the LDF group was 393 
an increase in the relative abundance of Bifidobacterium (p = 0.001) (Figure 5 + 394 
Supplemental Table 7). The prebiotic intervention did, however, lead to a number of 395 
significant changes in the HDF group including a significant increase in Bifidobacterium (p < 396 
0.001) and Faecalibacterium relative abundance (p = 0.010), and a significant reduction in 397 
Coprococcus (p = 0.010), Dorea (p = 0.043) and Ruminococcus (Lachnospiraceae family) 398 
relative abundance (p = 0.032) (Figure 5 + Supplemental Table 8). There was a trend towards 399 
a reduction in Shannon index (p = 0.060) in the HDF group and an increased in Chao index 400 
(p = 0.060) in the LDF group during the prebiotic intervention (Supplemental Table 2).  401 
The unweighted UniFrac distance principal co-ordinate analysis biplots (β diversity) 402 
demonstrate that there were large inter-individual variability in whole community microbiota 403 
responses to the inulin-type fructan prebiotic (Figure 6). For example, participant 32 (LDF) 404 
and 28 (HDF) harboured gut microbiota communities that were more responsive to the 405 
inulin-type fructan prebiotic as their before (black dot) and after (grey dot) prebiotic 406 
intervention samples are a distance away from each other. However, participant 19 (LDF) 407 
and 03 (HDF) before (black dot) and after (grey dot) prebiotic intervention samples cluster 408 
together suggesting that their gut microbiota communities were less responsive to the inulin-409 
type fructan prebiotic. There was, however, no significant difference in how the gut 410 
microbiota communities responded to the inulin-type fructan between the LDF and HDF 411 
groups (p = 0.997).  412 
The between dietary fibre group comparison demonstrated that there were no 413 
differences in phylum level gut microbiota response to the prebiotic between the LDF and 414 
HDF groups (Table 5). There were also no differences in prebiotic driven SCFA production 415 
between the LDF and HDF groups (Table 5). The gut microbiota did, however, respond 416 
differently between the LDF and HDF groups at a genus level for Lactobacillus, an unknown 417 
genus of Ruminococcaceae and Faecalibacterium (Figure 7). There was minimal change  in 418 
Lactobacillus relative abundance due to the prebiotic in the HDF group; however, 419 
Lactobacillus increased from 0.6% to 3.0% in the LDF group (p = 0.025). The relative 420 
abundance of an unknown genus of Ruminococcaceae increased in the HDF group but 421 
decreased  in the LDF group (p = 0.018). The relative abundance of Faecalibacterium 422 
increased more markedly in the HDF group than the LDF group  (p = 0.009) (Table 5). 423 
 424 
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Correlation between baseline bifidobacteria concentrations and change in bifidobacteria  425 
The quantitative PCR data was used to determine whether there was a correlation between 426 
baseline bifidobacteria concentrations and change in bifidobacteria concentrations due to the 427 
prebiotic intervention. A significant correlation was demonstrated for both the LDF (p = 428 
0.017) and HDF (p = 0.004) groups. The strength of the correlation was similar between the 429 
dietary fibre groups (Figure 8). 430 
 431 
DISCUSSION 432 
In the present study, the inulin-type fructan prebiotic led to several microbial changes 433 
in the whole cohort including an increase in Bifidobacterium and a decrease in Coprococcus, 434 
Dorea, Ruminococcus (Lachnospiraceae family) and Oscillospira relative abundances. There 435 
was also a trend towards an increase in Faecalibacterium relative abundance. Previous 436 
inulin-type fructan prebiotic intervention studies have demonstrated similar results with 437 
increases in Bifidobacterium and/or Faecalibacterium being reported in a number of studies 438 
(14,36–39). Short-chain fatty acid concentrations did not differ after the prebiotic 439 
intervention. In vitro studies have shown that inulin-type fructan prebiotics lead to an 440 
enhanced production of butyrate (40,41); however, this result is often not replicated in human 441 
prebiotic intervention studies (35,38,39). This is not overly surprising as over 95% of the 442 
SCFAs produced in the human colon are used by the microbiota that reside within the gut, are 443 
rapidly utilised by colonocytes and are absorbed into the hosts systemic circulation (42,43). 444 
Additionally, there were no significant changes in appetite ratings during the prebiotic 445 
intervention phase in the whole cohort.   446 
Interestingly, categorisation into LDF and HDF groups led to a number of distinctions 447 
in gut microbiota response within each dietary fibre group. In the LDF group, the only 448 
significant genus level microbiota change elicited by the inulin-type fructan prebiotic was an 449 
increase in Bifidobacterium relative abundance. In the HDF group, the inulin-type fructan 450 
prebiotic led to a significant increase in the relative abundance of Bifidobacterium and 451 
Faecalibacterium and a significant reduction in Coprococcus, Dorea and Ruminococcus 452 
(Lachnospiraceae family). The LDF group appeared to harbour a gut microbiota community 453 
that were more resilient to change and, therefore, less responsive to the inulin-type fructan 454 
prebiotic than the HDF group. A study conducted by Eid and co-authors (17) demonstrated 455 
that individuals with an average dietary fibre intake of 18 g/d hosted gut microbiota that were 456 
more stable to a palm date intervention. In their study individuals with an average dietary 457 
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fibre intake of 18 g/d were classified as HDF, whereas, in the present study LDF consumers 458 
had an average dietary fibre intake of 18 g/d. A recent study, which used germ-free 459 
(gnotobiotic) mice colonised with human gut microbiota from donors with two varying 460 
dietary patterns (typical American style dietary pattern [AMER] or a plant-rich, calorie-461 
restricted diet with optimal nutrient composition [CRON]), demonstrated that mice 462 
inoculated with AMER microbiota were less responsive to the CRON type diet when 463 
compared to mice inoculated with CRON microbiota (18). A recent in vitro batch 464 
fermentation study demonstrated that donors with healthier dietary patterns harboured gut 465 
microbiota that were better equipped at utilising fermentable carbohydrates found in grains 466 
compared to donors with less healthy dietary patterns (44). Therefore, the HDF group in the 467 
present study may have gut microbiota consortia that are metabolically more capable of 468 
utilising high amounts of fermentable substrates as their habitual diet is already high in these 469 
substrates.   470 
The between dietary fibre group comparison demonstrated that there were several 471 
bacterial genera that responded in a distinctive manner between the LDF and HDF groups. 472 
The inulin-type fructan prebiotic led to an increase in the relative abundance of 473 
Faecalibacterium  and an unknown genus of Ruminococcaceae , and minimal change in 474 
Lactobacillus relative abundance in the HDF group. In the LDF group, the inulin-type fructan 475 
prebiotic led to an increase in the relative abundance of Lactobacillus, minimal change in 476 
Faecalibacterium relative abundance and a reduction in the relative abundance of an 477 
unknown genus of Ruminococcaceae . It is likely that the whole cohort bacterial taxa results 478 
may have changed if the number of LDF and HDF participants recruited were different. In 479 
the present study, the data from more HDF than LDF consumers (20 and 14 participants; 480 
respectively) were used in the analysis. If the proportion of recruited HDF to LDF 481 
participants differed from the present study, then this could have had implications on the 482 
whole cohort results. For example, if more LDF than HDF consumers were recruited the 483 
prebiotic may have led to a significant increase in the relative abundance of Lactobacillus.  484 
Host-specific responses, such as appetite rating changes and gastrointestinal 485 
symptoms, were significantly influenced by the inulin-type fructan prebiotic in the HDF 486 
group only. The HDF group reported a significantly higher frequency of moderate flatulence, 487 
an increase in fullness and satisfaction after lunch and a reduction in hunger after dinner due 488 
to the inulin-type fructan prebiotic. One of the key differences in gut microbiota response to 489 
the prebiotic intervention between dietary fibre groups was the significant increase in 490 
Faecalibacterium relative abundance observed only in the HDF group. Butyrate and CO2
  are 491 
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primary metabolic by-products of indigestible substrate fermentation by Faecalibacterium in 492 
the colon (45). A primary component of flatus is CO2
 gas (46) and butyrate has been shown 493 
to be involved in regulating appetite-associated gut hormones (47). Therefore, it is plausible 494 
that the significant change in appetite ratings and the increased frequency of moderate 495 
flatulence experienced by the HDF group after the prebiotic intervention may be associated 496 
with the increased abundance of Faecalibacterium. Nevertheless, further investigation is 497 
required to demonstrate whether a link between Faecalibacterium and host response in 498 
healthy individuals exists.       499 
Consideration towards inter-individual variability in gut microbiota responsiveness 500 
will be particularly important when researching the prebiotic potential of a given dietary 501 
intervention for the first time. If a greater proportion of participants with less responsive gut 502 
microbiota communities are recruited then it may appear that the dietary intervention does 503 
not have an influence on the gut microbiota which may not be representative of the true 504 
prebiotic efficacy of the dietary intervention for all participants. Gaining additional insight 505 
into the factors which influence gut microbiota responsiveness, so they can be controlled for 506 
more effectively, will help determine the true prebiotic efficacy of a dietary intervention and 507 
provide better consistency of results between studies.  508 
 Quantitative PCR data were utilised to investigate whether a correlation between 509 
baseline bifidobacteria concentrations and prebiotic driven change in bifidobacteria 510 
concentrations exists in our study cohort. We also aimed to determine whether the strength of 511 
the correlation differed between the LDF and HDF groups. A significant correlation did exist 512 
between baseline bifidobacteria concentration and prebiotic driven change in bifidobacteria 513 
concentration with lower baseline bifidobacteria concentrations being correlated with a more 514 
pronounced bifidogenic response. The strength of the correlation did not differ between the 515 
LDF and HDF groups, suggesting that habitual dietary fibre intakes do not have an influence 516 
on the correlation. The majority of previous studies are in agreement with our results as they 517 
have also observed that lower baseline bifidobacteria concentrations lead to a more 518 
pronounced increase in bifidobacteria in response to a dietary intervention (12–16).  519 
There are a number of strengths of this study including the robust study design: a 520 
randomised, double-blind, placebo-controlled, cross-over human intervention study. This is 521 
also the first study to recruit participants based on pre-defined habitual dietary fibre intake 522 
categories to demonstrate what influence habitual dietary fibre intake has on gut microbiota 523 
responsiveness. Another strength of this study is the utilisation of next-generation sequencing 524 
technology which allowed for the characterisation of the whole microbial community rather 525 
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than focusing on changes that occur in only select bacterial taxa. A limitation of the present 526 
study is that the interpretation of our results is limited to inulin-type fructan prebiotic 527 
interventions, in particular, a mixed inulin:fructo-oligosaccharide prebiotic. Numerous other 528 
fermentable carbohydrates have a proven prebiotic effect, including galacto-oligosaccharides 529 
(GOS), however, the impact of habitual dietary fibre intake on the responsiveness of the gut 530 
microbiota to other prebiotics has not been published previously, nor was it investigated here. 531 
The microbially-derived enzymes, fructanase (responsible for fructan fermentation) and β-532 
Galactosidase (responsible for GOS fermentation) (48) are encoded on various bacteria and 533 
therefore the diet-dependent effects on prebiotic specificity may be different for different 534 
prebiotics (49). The influence habitual dietary fibre intake has on the responsiveness of the 535 
gut microbiota to other dietary interventions, such as GOS, calorie restriction, increased 536 
resistant starch and high wholegrains diets, will need to be researched in the future.  537 
In conclusion, it is difficult to predict how the gut microbiota will respond to a dietary 538 
intervention. Gaining a better understanding of the factors implicated in inter-individual 539 
variability in gut microbiota responsiveness may help improve dietary intervention success 540 
and subsequently enhance human health outcomes. In this study, we identified that 541 
individuals with HDF intakes have a greater gut microbiota response to an inulin-type fructan 542 
prebiotic. These individuals also experienced greater benefits in appetite but reported more 543 
gastrointestinal symptoms. Future studies aiming to modulate the gut microbiota using an 544 
inulin-type fructan prebiotic should take habitual dietary fibre intake into account either when 545 
recruiting participants or during data analysis to help minimise the influence inter-individual 546 
variability in gut microbiota responsiveness has on study outcomes. 547 
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FIGURE LEGENDS 
Figure 1- Consolidated Standards of Reporting Trials (CONSORT) flow diagram.  
 
Figure 2- Participant flow through the study including measurements, questionnaires and 
samples taken at each research unit visit. IP: intervention phase, Fructan-FFQ: fructan food 
frequency questionnaire, BodPod: air displacement plethysmography. 
 
Figure 3- Baseline differences in the average number of food group serves consumed per day 
(as assessed using four 3-day diet records) between the low and high dietary fibre groups. 
Changes that are significantly different (p < 0.05) between dietary fibre groups are indicated 
with an asterisks (*) as analysed by a Mann-Whitney test. 
 
Figure 4- Mean phylum level relative abundance (%) before and after the placebo and 
prebiotic intervention phases for the low (LDF) and high habitual dietary fibre (HDF) groups. 
Values that are significantly different from the placebo intervention and prebiotic before 
intervention are indicated with an asterisk; *p < 0.05, **p < 0.01. 
 
Figure 5- Mean genus level relative abundance (%) before and after the placebo and prebiotic 
intervention phases for the low (LDF) and high habitual dietary fibre (HDF) groups. After 
intervention values that are significantly different from the placebo intervention and prebiotic 
before intervention (or in the case of Dialister significantly different from those of the 
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prebiotic intervention and placebo before intervention) are indicated with an asterisk; *p < 
0.05, **p < 0.01. 
 
Figure 6- Principal co-ordinate analysis biplots (unweighted UniFrac distances) illustrating 
the between sample differences in bacterial taxa (β-diversity) before (black dots) and after the 
prebiotic intervention (grey dots) for the low and high habitual dietary fibre groups. 
Participant IDs are shown on the biplot (i.e. 03). The further apart a participants’ samples are 
from each other the greater the whole community microbiota response was to the inulin-type 
fructan prebiotic. The white shaded spheres represent the 10 most abundant bacterial taxa. 
The spheres that cluster in the middle of the graphs which are not labelled include the 
following bacterial taxa: Coprococcus; Bacteroides; Ruminococcus; Collinsella; 
Lachnospiraceae, unknown genus; Blautia and Ruminococcaceae, unknown genus. The 
position and size of the sphere indicates the bacterial taxa that are the most influential in 
driving the separation of the samples.   
 
Figure 7- Mean genus level changes after the prebiotic intervention between the low and high 
dietary fibre groups. A significant change (p < 0.05) is indicated with an asterisk (*) as 
analysed by a two-way repeated-measures ANOVA (blocked by participant) and least 
significant difference test. 
 
Figure 8- The correlation between baseline bifidobacteria concentrations (Before [log]) and 
change in bifidobacteria concentrations (After over before [log]) during the prebiotic 
intervention between the low and high dietary fibre groups. Bifidobacteria concentrations 
were determined using quantitative PCR. P values <0.05 are considered significant as 
analysed by a Pearson’s rank correlation test. 
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TABLES 
    TABLE 1 
    Baseline dietary intake differences between the low and high dietary fibre groups1 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
  1 Mann-Whitney test. Significant results (p < 0.05) are in bold. SD: standard deviation 
 
 
 
TABLE 2 
Participant characteristic comparison between the low and high dietary fibre groups1 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Chi-squared test and unpaired t-test. Significant results (p < 0.05) are in bold. Values are means 
± standard deviations. ^ Activity level of 5 is seated work with some moving around and strenuous 
leisure activity 
 
 
 
 
 
 
 
Low dietary fibre (n=14) High dietary fibre (n=20)   
Dietary intake Mean SD Mean SD P value 
Energy (kJ/d) 7161.1 2285.2 10013.9 2769.8 0.002 
Protein (g/d) 83.1 28.5 112.7 45.5 0.066 
Total fat (g/d) 67.8 26.0 95.9 29.7 0.012 
Saturated fat (g/d) 26.5 13.3 33.3 14.6 0.259 
Polyunsaturated fat (g/d) 10.8 4.2 16.3 5.9 0.005 
Monounsaturated fat (g/d) 24.6 8.9 38.0 10.8 0.001 
Carbohydrate (g/d) 178.0 83.0 241.3 84.0 0.015 
Sugars (g/d) 77.8 47.0 106.2 40.4 0.051 
Starch (g/d) 99.2 39.5 132.0 59.9 0.104 
Dietary fibre (g/d) 18.0 3.4 38.6 13.0 <0.001 
Dietary fibre (g/d) per 1000kJ 2.7 0.8 3.9 1.0 <0.001 
Total Inulin (g/d) 3.1 1.3 2.9 1.1 0.796 
Total oligofructose (g/d) 3.0 1.2 2.8 1.0 0.769 
Water (g/d) 2048.2 746.3 2781.4 1428.1 0.104 
Alcohol (g/d) 3.1 6.8 4.2 12.3 0.565 
Energy from protein (%) 20.6 8.0 19.1 4.5 0.877 
Energy from fat (%) 34.4 5.2 35.9 8.5 0.986 
Energy from saturated fat (%) 13.1 3.9 12.3 4.5 0.457 
Energy from carbohydrate (%) 40.6 10.4 39.3 7.4 0.823 
Energy from alcohol (%) 1.2 2.6 1.0 2.7 0.601 
Energy from fibre (%) 2.2 0.7 3.1 0.8 <0.001 
 
Low dietary fibre 
(n=14) 
High dietary fibre 
(n=20) P value 
Age (years) 37.7 ± 10.6 37.2 ± 14.4 0.902 
BMI (kg/m2) 24.3 ± 2.7 22.5 ± 2.8 0.061 
Male : Female 6 : 8 7 : 13 0.643 
Fat mass (%) 27.5 ± 7.5 20.3 ± 9.0 0.021 
Fat free mass (%) 72.6 ± 7.5 79.7 ± 9.0 0.021 
Ethnicity (no.)  
 
0.938 
NZ European 6 9 
 Maori 1 2 
 Other 7 9 
 Skip meals (Yes : No) 6 : 8 5 : 15 0.273 
Snack consumed per day (no.) 2.0 ± 0.9 2.4 ± 0.6 0.091 
Activity level^ 5.1 ± 0.9 5.6 ± 1.2 0.183 
Stools passed per week (no.) 6.7 ± 3.6 8.6 ± 3.8 0.155 
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TABLE 3 
Baseline short-chain fatty acid concentrations and bacterial taxa in the low and high dietary fibre groups1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Mann-Whitney test. Mean values are significantly different from the low dietary fibre group. *p < 0.05, ^trend towards  
significance (p < 0.1). SD: standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Low dietary fibre (n=14) High dietary fibre (n=20)  
  Mean SD Mean SD P value 
Short-chain fatty acids (µmol/g)           
Acetate 28.97 18.23 33.32 19.74 0.592 
Butyrate 7.77 5.10 9.08 5.80 0.545 
Propionate 9.99 6.31 10.05 8.90 0.666 
Sum of short-chain fatty acids 51.02 29.00 56.57 33.12 0.877 
Phylum (% relative abundance)      
Actinobacteria 13.98 9.42 8.87 5.97 0.104 
Bacteroidetes 11.31 8.94 16.82 11.44 0.169 
Firmicutes 72.82 8.79 72.12 12.15 0.931 
Proteobacteria 0.65 0.93 0.47 0.47 0.823 
Verrucomicrobia 0.33 0.58 0.26 0.33 0.304 
Genus (% relative abundance)      
Bifidobacterium 9.81 7.78 4.51^ 4.10 0.066 
Collinsella 2.95 3.09 3.15 2.69 0.616 
Bacteroides 6.77 5.01 6.81 3.66 0.931 
Prevotella 2.94 4.89 6.79 11.03 0.666 
Lactobacillus 0.59 1.29 0.03 0.06 0.609 
Lachnospiraceae, other, unknown genus 2.38 1.46 1.50* 0.78 0.043 
Lachnospiraceae, unknown genus 11.85 7.20 13.04 5.58 0.377 
Blautia 10.42 5.57 9.53 4.36 0.569 
Coprococcus 3.83 2.13 4.97 2.74 0.204 
Dorea 2.01 1.22 1.57 0.71 0.341 
Ruminococcus (Lachnospiraceae) 2.55 1.99 1.81 1.20 0.306 
Ruminococcaceae, unknown genus 15.95 5.08 14.74 3.12 0.569 
Faecalibacterium 0.39 0.29 0.42 0.18 0.500 
Oscillospira 1.21 0.65 1.00 0.42 0.478 
Ruminococcus (Ruminococcaceae) 5.80 4.26 5.27 3.47 0.849 
Dialister 1.00 1.65 1.12 1.81 0.568 
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TABLE 4 
Short-chain fatty acid concentration and bacterial taxa changes during the placebo and prebiotic intervention phases in the whole cohort1  
 
 
1 Two-way repeated-measures ANOVA (blocked by participant) and least significant difference test. Mean values are significantly different 
from those of the placebo intervention and prebiotic before intervention or in the case of Dialister different from those of the prebiotic 
intervention and placebo before intervention; *p < 0.05, **p < 0.01, ^trend towards significance (p < 0.1). SD: standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Placebo (n = 33) Prebiotic (n = 34) 
  Before intervention After intervention Before intervention After intervention 
  Mean SD Mean SD Mean SD Mean SD 
Short-chain fatty acids (µmol/g)  
Acetate 31.78 17.80 33.80 18.97 31.53 18.97 39.50 20.96 
Butyrate 9.75 6.12 9.44 5.62 8.54 5.48 10.16 5.62 
Propionate 10.09 6.19 11.63 7.78 10.03 7.83 11.94 7.47 
Sum of short-chain fatty acids 55.52 28.69 59.48 32.28 54.28 31.16 65.51 32.48 
Phylum (% relative abundance) 
Actinobacteria 10.88 6.43 10.84 7.24 10.98 7.87 19.95** 10.20 
Bacteroidetes 14.30 12.09 13.09 8.39 14.55 10.70 12.46 8.33 
Firmicutes 72.90 11.31 73.85 11.02 72.41 10.75 65.71** 11.03 
Proteobacteria 0.43 0.40 0.51 0.61 0.54 0.69 0.36^ 0.42 
Verrucomicrobia 0.33 0.66 0.38 0.85 0.29 0.45 0.17 0.33 
Genus (% relative abundance) 
Bifidobacterium 6.56 5.21 6.50 5.88 6.69 6.37 15.07** 8.54 
Collinsella 3.36 2.52 3.15 2.80 3.07 2.82 3.81 2.79 
Bacteroides 6.49 3.81 6.45 4.31 6.80 4.19 5.86 3.40 
Prevotella  5.36 12.16 3.66 5.98 5.20 9.12 4.85 7.98 
Lactobacillus 0.24 0.92 0.44 1.96 0.26 0.86 1.26 3.83 
Lachnospiraceae, other, unknown genus 2.07 1.11 1.91 1.24 1.86 1.18 1.55 0.62 
Lachnospiraceae, unknown genus 13.27 5.79 13.43 5.62 12.55 6.22 14.74 6.30 
Blautia 10.78 5.81 9.45 4.43 9.90 4.83 7.67 3.88 
Coprococcus 3.80 1.83 4.16 2.20 4.50 2.54 3.55* 1.65 
Dorea 1.65 0.86 1.61 0.86 1.75 0.96 1.20* 0.66 
Ruminococcus (Lachnospiraceae) 1.85 1.66 1.95 1.64 2.11 1.59 1.15** 1.04 
Ruminococcaceae, unknown genus 16.33 4.82 16.86 4.29 15.24 4.01 14.50 4.12 
Faecalibacterium 0.47 0.32 0.53 0.30 0.41 0.22 0.61^ 0.32 
Oscillospira 1.10 0.67 1.11 0.70 1.08 0.53 0.78* 0.46 
Ruminococcus (Ruminococcaceae) 5.60 3.73 5.52 4.00 5.49 3.76 4.40 3.32 
Dialister 0.77 1.15 1.00^ 1.56 1.07 1.72 0.94 1.59 
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TABLE 5 
Short-chain fatty acid concentrations and bacterial taxa before and after the prebiotic intervention in low and high dietary fibre groups1  
 Low dietary fibre (n=14) High dietary fibre (n=20)  
Before 
intervention 
After  
intervention 
C
h
a
n
g
e Before 
intervention 
After 
 intervention 
C
h
a
n
g
e 
Mean SD Mean SD Mean SD Mean SD P value 
Short-chain fatty acids (µmol/g)              
Acetate 29 18.2 34.3 22.3 5.3 33.3 19.7 43.2 19.7 9.9 0.534 
Butyrate 7.8 5.1 8.3 5.3 0.5 9.1 5.8 11.5 5.6 2.4 0.375 
Propionate 10 6.3 10.9 7.1 0.9 10.1 8.9 12.7 7.8 2.6 0.424 
Sum of short chain fatty acids 51 29 57.6 34 6.6 56.6 33.1 71.1 31.1 14.5 0.475 
Phylum (% relative abundance)            
Actinobacteria 14 9.4 23.2 9.6 9.2 8.9 6 17.7 10.2 8.8 0.907 
Bacteroidetes 11.3 8.9 9.6 5.4 -1.7 16.8 11.4 14.5 9.5 -2.3 0.829 
Firmicutes 72.8 8.8 66 9.7 -6.9 72.1 12.2 65.5 12.1 -6.6 0.933 
Proteobacteria 0.7 0.9 0.3 0.4 -0.4 0.5 0.5 0.4 0.5 -0.1 0.188 
Verrucomicrobia 0.3 0.6 0.2 0.5 -0.1 0.3 0.3 0.2 0.2 -0.1 0.947 
Genus (% relative abundance)            
Bifidobacterium 9.8 7.8 18 7.9 8.2 4.5 4.1 13 8.6 8.5 0.9 
Collinsella 3 3.1 3.9 3.2 1 3.2 2.7 3.7 2.5 0.6 0.681 
Bacteroides 6.8 5 5.7 3.9 -1 6.8 3.7 6 3.1 -0.9 0.909 
Prevotella 2.9 4.9 2.5 3.6 -0.5 6.8 11 6.5 9.7 -0.3 0.898 
Lactobacillus 0.6 1.3 3 5.6 2.4 0 0.1 0.1 0.2 0.1 0.025 
Lachnospiraceae, other, unknown genus 2.4 1.5 1.8 0.6 -0.5 1.5 0.8 1.4 0.5 -0.2 0.261 
Lachnospiraceae, unknown genus 11.9 7.2 13.2 7.4 1.4 13 5.6 15.8 5.4 2.8 0.522 
Blautia 10.4 5.6 8.1 4.1 -2.3 9.5 4.4 7.4 3.8 -2.2 0.917 
Coprococcus 3.8 2.1 3.1 1.9 -0.8 5 2.7 3.9 1.4 -1.1 0.65 
Dorea 2 1.2 1.2 0.5 -0.8 1.6 0.7 1.2 0.8 -0.4 0.253 
Ruminococcus (Lachnospiraceae) 2.6 2 1.2 1.3 -1.3 1.8 1.2 1.1 0.8 -0.7 0.249 
Ruminococcaceae, unknown genus 16 5.1 13.1 4.8 -2.9 14.7 3.1 15.5 3.3 0.8 0.018 
Faecalibacterium 0.4 0.3 0.5 0.3 0.1 0.4 0.2 0.7 0.3 0.3 0.009 
Oscillospira 1.2 0.7 0.9 0.5 -0.3 1 0.4 0.7 0.5 -0.3 0.986 
Ruminococcus (Ruminococcaceae) 5.8 4.3 5 4 -0.8 5.3 3.5 3.9 2.8 -1.3 0.617 
Dialister 1 1.7 1.1 2.1 0.1 1.1 1.8 0.8 1.1 -0.3 0.356 
1 Two-way repeated-measures ANOVA (blocked by participant) and least significant difference test. The changes in bacterial relative 
abundance that were significantly different between the low and high dietary fibre groups are in bold (p < 0.05). SD: standard deviation. 
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